Interim analysis NCT04046094: IV Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients (CI-MIBC)

Plenary: Friday Morning: Late-Breaking Abstract: PLLBA-01: Final clinical results of pivotal trial of IL-15R&[alpha]Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) CIS and Papillary Cohorts

Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Results from the Phase 2 QUEST Study

Plenary: Friday Morning: Late-Breaking Abstract: PLLBA-02: Impact of 18F-rhPSMA-7.3 PET on upstaging of patients with prostate cancer recurrence: Results from the prospective, phase 3, multicenter, SPOTLIGHT study

Disease-Free Survival With Longer Follow-Up From the CheckMate 274 Trial of Adjuvant Nivolumab in Patients After Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma

Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide or Placebo Plus Androgen Deprivation Therapy Who Had Prior Local Therapy: Post Hoc Analysis of the Phase 3 ARCHES Trial

Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Pooled Safety Analyses from Randomized Controlled Studies

Site-specific early response patterns in advanced RCC patients treated with Nivolumab and Ipilimumab compared with Sunitinib therapy

Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world multicenter analysis

Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Safety Analysis from the Randomized Phase 3 HERO Study

A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients (pts) With Muscle-Invasive Bladder Cancer (NCT01938573)

Efficacy and Safety of Darolutamide in Nonmetastatic Castration-resistant Prostate Cancer Patients With and Without Prior Local Therapy With Radical Prostatectomy or Radiotherapy

Two-Year Efficacy Follow-Up of a Phase I trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treat

A Phase II Study of Check Point Inhibitor; Durvalumab (MEDI4736) for Bacillus Calmette-Guerin Unresponsive Carcinoma in Situ of the Bladder

Impact of disease status heterogeneity of the STAMPEDE trial arm J population on oncological outcomes in high-risk nonmetastatic prostate cancer